Efficacy and safety of riociguat in combination therapy for patients with pulmonary arterial hypertension (PATENT studies)

Many patients with pulmonary arterial hypertension do not achieve treatment goals with monotherapy, and therefore combination therapy is becoming the standard of care. The soluble guanylate cyclase stimulator riociguat is licensed for the treatment of pulmonary arterial hypertension; here we present...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghofrani, Hossein-Ardeschir, Grünig, Ekkehard, Jansa, Pavel, Langleben, David, Rosenkranz, Stephan, Preston, Ioana R., Rahaghi, Franck, Sood, Namita, Busse, Dennis, Meier, Christian, Humbert, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7366414/
https://www.ncbi.nlm.nih.gov/pubmed/32728421
http://dx.doi.org/10.1177/2045894020942121

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7366414/
https://www.ncbi.nlm.nih.gov/pubmed/32728421
http://dx.doi.org/10.1177/2045894020942121

Ejemplares similares